529 related articles for article (PubMed ID: 24794210)
1. Cardiotoxicity of systemic agents used in breast cancer.
Ades F; Zardavas D; Pinto AC; Criscitiello C; Aftimos P; de Azambuja E
Breast; 2014 Aug; 23(4):317-28. PubMed ID: 24794210
[TBL] [Abstract][Full Text] [Related]
2. [Chemotherapy-induced cardiotoxicity: Incidence, diagnosis and prevention].
Nelson-Veniard M; Thambo JB
Bull Cancer; 2015; 102(7-8):622-6. PubMed ID: 25935231
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
Castrellon AB; Glück S
Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
[TBL] [Abstract][Full Text] [Related]
4. Cardiac complications and manifestations of chemotherapy for cancer.
Khawaja MZ; Cafferkey C; Rajani R; Redwood S; Cunningham D
Heart; 2014 Jul; 100(14):1133-40. PubMed ID: 24326899
[No Abstract] [Full Text] [Related]
5. Cardiotoxicity associated with the use of trastuzumab in breast cancer patients.
Perik PJ; de Korte MA; van Veldhuisen DJ; Gietema JA; Sleijfer DT; de Vries EG
Expert Rev Anticancer Ther; 2007 Dec; 7(12):1763-71. PubMed ID: 18062750
[TBL] [Abstract][Full Text] [Related]
6. The cardiac safety of trastuzumab in the treatment of breast cancer.
Chien AJ; Rugo HS
Expert Opin Drug Saf; 2010 Mar; 9(2):335-46. PubMed ID: 20175700
[TBL] [Abstract][Full Text] [Related]
7. [Towards an integrated approach to cardiovascular toxicities related to the treatments of breast cancer].
Tanz R; Magne N; Annede P; Mery B; Jacob J; Bauduceau O; Trone JC; Guichard JB; Meillan N; Kirova Y; Vedrine L; Chargari C
Bull Cancer; 2014; 101(7-8):730-40. PubMed ID: 25091656
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.
Telli ML; Hunt SA; Carlson RW; Guardino AE
J Clin Oncol; 2007 Aug; 25(23):3525-33. PubMed ID: 17687157
[TBL] [Abstract][Full Text] [Related]
9. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Zambelli A; Della Porta MG; Eleuteri E; De Giuli L; Catalano O; Tondini C; Riccardi A
Breast; 2011 Apr; 20(2):176-83. PubMed ID: 21146409
[TBL] [Abstract][Full Text] [Related]
10. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer.
Suter TM; Cook-Bruns N; Barton C
Breast; 2004 Jun; 13(3):173-83. PubMed ID: 15177418
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be?
Morris PG; Hudis CA
J Clin Oncol; 2010 Jul; 28(21):3407-10. PubMed ID: 20530269
[No Abstract] [Full Text] [Related]
12. Trastuzumab therapy in Australia: which patients with HER2+ metastatic breast cancer are assessed for cardiac function?
Lu CY; Srasuebkul P; Drew AK; Chen K; Ward RL; Pearson SA
Breast; 2013 Aug; 22(4):482-7. PubMed ID: 23664254
[TBL] [Abstract][Full Text] [Related]
13. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.
Jensen BV
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S15-21. PubMed ID: 16781285
[TBL] [Abstract][Full Text] [Related]
14. Endothelial dysfunction as a determinant of trastuzumab-mediated cardiotoxicity in patients with breast cancer.
Sandoo A; Kitas GD; Carmichael AR
Anticancer Res; 2014 Mar; 34(3):1147-51. PubMed ID: 24596352
[TBL] [Abstract][Full Text] [Related]
15. Anticancer agents and cardiotoxicity.
Ng R; Better N; Green MD
Semin Oncol; 2006 Feb; 33(1):2-14. PubMed ID: 16473642
[TBL] [Abstract][Full Text] [Related]
16. Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes.
Gianni L; Salvatorelli E; Minotti G
Cardiovasc Toxicol; 2007; 7(2):67-71. PubMed ID: 17652806
[TBL] [Abstract][Full Text] [Related]
17. Cardiotoxicity of novel HER2-targeted therapies.
Sendur MA; Aksoy S; Altundag K
Curr Med Res Opin; 2013 Aug; 29(8):1015-24. PubMed ID: 23692263
[TBL] [Abstract][Full Text] [Related]
18. Cardiotoxicity debated for anthracyclines and trastuzumab in breast cancer.
Brower V
J Natl Cancer Inst; 2013 Jun; 105(12):835-6. PubMed ID: 23733910
[No Abstract] [Full Text] [Related]
19. Reversibility of trastuzumab cardiotoxicity: is the concept alive and well?
Ewer MS; Tan-Chiu E
J Clin Oncol; 2007 Dec; 25(34):5532-3; author reply 5533-4. PubMed ID: 18048835
[No Abstract] [Full Text] [Related]
20. Chemotherapy-induced cardiotoxicity in women.
Dempsey KS
Crit Care Nurs Clin North Am; 2008 Sep; 20(3):343-50. PubMed ID: 18644518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
